Skip to content
Screener

Bausch + Lomb BLCO Shares (Diluted)

Shares (Diluted) at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
2.4B+0.9%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
195M-2.8%
Glaukos logo
GlaukosGKOS
58.8M+2.8%
LENSAR, Inc. logo
LENSAR, Inc.LNSR
15.4M+31.0%
HRO
HarrowHROW
37.2M+3.9%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
224.1M+32.3%

Other financials

Income statement

See full
Revenue$1.4B+9.1%
Operating income$83.0M+855%
Net income-$14.0M+77.4%
EPS (diluted)-$0.04+77.8%

Balance sheet

See full
Cash & equivalents$378.0M+39.0%
Total debt$5.1B+2.4%
Total equity$6.4B-1.0%
Total assets$13.9B+0.2%

Cash flow

See full
Operating cash flow$153.0M+337%
CapEx$71.0M-20.2%
Free cash flow$82.0M+252%

Valuation

See full
Market cap$5.84B+17.0%
Enterprise value$10.54B+8.9%
P/S1.1×+0.1×

Profitability

See full
Operating margin6.1%+5.3pp
Net margin-3.2%-1.0pp
FCF margin-3.4%0.0pp

Returns & leverage

See full
Return on equity-2.7%-0.7pp
Debt / equity0.8×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Bausch + Lomb in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: Bausch + Lomb’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:17 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001860742-26-000088
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Loss before provision for income taxes(11)(147)(75)(327)
Benefit from (provision for) income taxes189(5)58
Net loss(10)(58)(80)(269)
Net income attributable to noncontrolling interest(4)(4)(5)(5)
Net loss attributable to Bausch + Lomb Corporation$(14)$(62)$(85)$(274)
Basic and diluted loss per share attributable to Bausch + Lomb Corporation$(0.04)$(0.18)$(0.24)$(0.78)
Basic weighted-average common shares357.1353.7356.2353.3
Diluted weighted-average common shares357.1353.7356.2353.3

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Bausch + Lomb's shares (diluted)?
Bausch + Lomb (BLCO) reported shares (diluted) of 357.1M in Q2 2026.
How has Bausch + Lomb's shares (diluted) changed year-over-year?
Bausch + Lomb's shares (diluted) increased by 1.0% year-over-year, from 353.7M to 357.1M.
What is the long-term trend for Bausch + Lomb's shares (diluted)?
Over 4 years (2021 to 2025), Bausch + Lomb's shares (diluted) has grown at a 0.3% compound annual growth rate (CAGR), from 1.4B to 1.4B.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about Bausch + Lomb's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude